![Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial | Nature Medicine Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01455-x/MediaObjects/41591_2021_1455_Fig1_HTML.png)
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial | Nature Medicine
![Frontiers | Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study Frontiers | Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study](https://www.frontiersin.org/files/Articles/991662/fimmu-13-991662-HTML/image_m/fimmu-13-991662-g001.jpg)
Frontiers | Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study
![Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study - eBioMedicine Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study - eBioMedicine](https://www.thelancet.com/cms/asset/809030bb-7d71-4e9b-8626-223890e8d170/gr1.jpg)
Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study - eBioMedicine
Full article: Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits
![Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial - The Lancet Neurology Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/14e6eb1a-75e1-4664-a681-46f6dd5a4014/gr1.jpg)
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial - The Lancet Neurology
![Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download](https://images.slideplayer.com/36/10609964/slides/slide_10.jpg)
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
![Teva Class Action Claims Company Suppressed Competition For Generic Version Of MS Drug Copaxone - Top Class Actions Teva Class Action Claims Company Suppressed Competition For Generic Version Of MS Drug Copaxone - Top Class Actions](https://s40123.pcdn.co/wp-content/uploads/2022/03/shutterstock_2080603243.jpg.optimal.jpg)